Cargando…
Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer
BACKGROUND: Multimodal treatment strategies – perioperative chemotherapy (CTx) and radical surgery – are currently accepted as treatment standard for locally advanced gastric cancer. However, the role of adjuvant postoperative CTx (postCTx) in addition to neoadjuvant preoperative CTx (preCTx) in thi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991066/ https://www.ncbi.nlm.nih.gov/pubmed/27538392 http://dx.doi.org/10.1186/s12885-016-2708-0 |
_version_ | 1782448790977904640 |
---|---|
author | Lichthardt, Sven Kerscher, Alexander Dietz, Ulrich A. Jurowich, Christian Kunzmann, Volker von Rahden, Burkhard H. A. Germer, Christoph-Thomas Wiegering, Armin |
author_facet | Lichthardt, Sven Kerscher, Alexander Dietz, Ulrich A. Jurowich, Christian Kunzmann, Volker von Rahden, Burkhard H. A. Germer, Christoph-Thomas Wiegering, Armin |
author_sort | Lichthardt, Sven |
collection | PubMed |
description | BACKGROUND: Multimodal treatment strategies – perioperative chemotherapy (CTx) and radical surgery – are currently accepted as treatment standard for locally advanced gastric cancer. However, the role of adjuvant postoperative CTx (postCTx) in addition to neoadjuvant preoperative CTx (preCTx) in this setting remains controversial. METHODS: Between 4/2006 and 12/2013, 116 patients with locally advanced gastric cancer were treated with preCTx. 72 patients (62 %), in whom complete tumor resection (R0, subtotal/total gastrectomy with D2-lymphadenectomy) was achieved, were divided into two groups, one of which receiving adjuvant therapy (n = 52) and one without (n = 20). These groups were analyzed with regard to survival and exclusion criteria for adjuvant therapy. RESULTS: Postoperative complications, as well as their severity grade, did not correlate with fewer postCTx cycles administered (p = n.s.). Long-term survival was shorter in patients receiving postCTx in comparison to patients without postCTx, but did not show statistical significance. In per protocol analysis by excluding two patients with perioperative death, a shorter 3-year survival rate was observed in patients receiving postCTx compared to patients without postCTx (3-year survival: 71.2 % postCTx group vs. 90.0 % non-postCTx group; p = 0.038). CONCLUSION: These results appear contradicting to the anticipated outcome. While speculative, they question the value of post-CTx. Prospectively randomized studies are needed to elucidate the role of postCTx. |
format | Online Article Text |
id | pubmed-4991066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49910662016-08-20 Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer Lichthardt, Sven Kerscher, Alexander Dietz, Ulrich A. Jurowich, Christian Kunzmann, Volker von Rahden, Burkhard H. A. Germer, Christoph-Thomas Wiegering, Armin BMC Cancer Research Article BACKGROUND: Multimodal treatment strategies – perioperative chemotherapy (CTx) and radical surgery – are currently accepted as treatment standard for locally advanced gastric cancer. However, the role of adjuvant postoperative CTx (postCTx) in addition to neoadjuvant preoperative CTx (preCTx) in this setting remains controversial. METHODS: Between 4/2006 and 12/2013, 116 patients with locally advanced gastric cancer were treated with preCTx. 72 patients (62 %), in whom complete tumor resection (R0, subtotal/total gastrectomy with D2-lymphadenectomy) was achieved, were divided into two groups, one of which receiving adjuvant therapy (n = 52) and one without (n = 20). These groups were analyzed with regard to survival and exclusion criteria for adjuvant therapy. RESULTS: Postoperative complications, as well as their severity grade, did not correlate with fewer postCTx cycles administered (p = n.s.). Long-term survival was shorter in patients receiving postCTx in comparison to patients without postCTx, but did not show statistical significance. In per protocol analysis by excluding two patients with perioperative death, a shorter 3-year survival rate was observed in patients receiving postCTx compared to patients without postCTx (3-year survival: 71.2 % postCTx group vs. 90.0 % non-postCTx group; p = 0.038). CONCLUSION: These results appear contradicting to the anticipated outcome. While speculative, they question the value of post-CTx. Prospectively randomized studies are needed to elucidate the role of postCTx. BioMed Central 2016-08-18 /pmc/articles/PMC4991066/ /pubmed/27538392 http://dx.doi.org/10.1186/s12885-016-2708-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lichthardt, Sven Kerscher, Alexander Dietz, Ulrich A. Jurowich, Christian Kunzmann, Volker von Rahden, Burkhard H. A. Germer, Christoph-Thomas Wiegering, Armin Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer |
title | Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer |
title_full | Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer |
title_fullStr | Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer |
title_full_unstemmed | Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer |
title_short | Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer |
title_sort | original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991066/ https://www.ncbi.nlm.nih.gov/pubmed/27538392 http://dx.doi.org/10.1186/s12885-016-2708-0 |
work_keys_str_mv | AT lichthardtsven originalarticleroleofadjuvantchemotherapyinaperioperativechemotherapyregimenforgastriccancer AT kerscheralexander originalarticleroleofadjuvantchemotherapyinaperioperativechemotherapyregimenforgastriccancer AT dietzulricha originalarticleroleofadjuvantchemotherapyinaperioperativechemotherapyregimenforgastriccancer AT jurowichchristian originalarticleroleofadjuvantchemotherapyinaperioperativechemotherapyregimenforgastriccancer AT kunzmannvolker originalarticleroleofadjuvantchemotherapyinaperioperativechemotherapyregimenforgastriccancer AT vonrahdenburkhardha originalarticleroleofadjuvantchemotherapyinaperioperativechemotherapyregimenforgastriccancer AT germerchristophthomas originalarticleroleofadjuvantchemotherapyinaperioperativechemotherapyregimenforgastriccancer AT wiegeringarmin originalarticleroleofadjuvantchemotherapyinaperioperativechemotherapyregimenforgastriccancer |